Aflibercept (2.0 mg)
Aflibercept (2.0 mg) is a pharmaceutical drug with 15 clinical trials. Currently 7 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
7
trials recruiting
15
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy
Clinical Trials (15)
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema
A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema
The Endurance 1 Trial
Study for Recalcitrant Age Related Macular Degeneration
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
All 15 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 15